Company: RCUS
Filing Date: 2025-02-18
Form Type: 424B5
Source: 0001193125-25-028669
Chunk: 40

Company: Arcus Biosciences, Inc.
Filing Date: 2025-02-18
Form: 424B5
Chunk 40
---
 have a meaningful impact on patients.

Strategic Partnerships

Gilead

In 2020, we and Gilead Sciences, Inc., or Gilead, entered into an Option, License and Collaboration Agreement, or the Gilead Collaboration
Agreement, Common Stock Purchase Agreement, or the Stock Purchase Agreement, and Investor Rights Agreement. The Gilead Collaboration Agreement and the Stock Purchase Agreement were amended in 2021, and the Investor Rights Agreement was amended in
2022.

Under the Gilead Collaboration Agreement, Gilead obtained an exclusive license to our anti-PD-1 program (including zimberelimab)
and time-limited exclusive options to all of our then-current and future programs during the 10-year collaboration term. In 2021, Gilead obtained rights to our anti-TIGIT program (including domvanalimab and AB308), adenosine receptor antagonist
program (including etrumadenant) and CD73 program (including quemliclustat). For each program to which Gilead exercised or exercises its option, the parties will co-develop globally and co-commercialize the program in the United States, subject to
certain exceptions, and Gilead will have the right to commercialize the program outside of the United States, subject to the rights of our existing partners in certain territories.

Under the Stock Purchase Agreement, Gilead purchased common stock from us for $200 million in 2020 and $220 million in 2021, and has the
right, at its option from time to time until July 2025, to purchase up to a maximum ownership of 35% of our then-outstanding voting common stock. The Investor Rights Agreement provides for a three-year standstill, three-year lockup and the right to
designate two individuals to be appointed to

1

our Board of Directors. As of December 31, 2022, Gilead held approximately 18.9% of our outstanding common stock. Gilead has indicated that it may seek to maintain its ownership position through open market transactions and/or by potentially engaging us in a private transaction. We cannot guarantee that Gilead will maintain its ownership position or that we will enter into any new agreements for any such private transactions during the term of any offering. Taiho In 2017, we entered into an Option and License Agreement with Taiho Pharmaceutical Co., Ltd., or Taiho, pursuant to which Taiho was granted time-limited options to exclusively